On September 1, Novartis AG rose 5.22% in pre-market trading, trading at $159.26 per share, with turnover of $188,100. The movement comes amid a mixed set of developments in the company's neuroscience and autoimmune pipeline.

Novartis halted eight early- and mid-stage clinical trials of its CD19-targeting CAR-T cell therapy rap-cel in late August after three patients died from severe immune effector cell-associated hemophagocytic syndrome (IEC-HS). The paused trials covered indications including lupus, multiple sclerosis, and other autoimmune and neurological disorders. The company is conducting a comprehensive safety review in collaboration with independent monitoring boards and regulators. Notably, Novartis confirmed its oncology CAR-T pipeline remains unaffected. Bristol-Myers Squibb also precautionarily paused similar CAR-T trials.

Offsetting the setback, Novartis reported positive late-stage clinical trial results for remibrutinib, an oral therapy for multiple sclerosis, supporting the company's broader neuroscience strategy beyond cell therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)